Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MCO-020
- Development stage
- Preclinical
- Lead developer
- Nanoscope Therapeutics
- Modality
- AAV Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies, Lipid-mediated Delivery → Gene Addition/Replacement → Gene Therapies, Electrical: Electroporation → Physical Methods → Gene Addition/Replacement → Gene Therapies, Magnetic: Magnetofection → Physical Methods → Gene Addition/Replacement → Gene Therapies, Mechanical: Microinjection, microfluidics, gene gun → Physical Methods → Gene Addition/Replacement → Gene Therapies, Acoustic/Optical: Sonoporation, laser photoporation → Physical Methods → Gene Addition/Replacement → Gene Therapies, Pressure-driven: Hydrodynamic injection → Physical Methods → Gene Addition/Replacement → Gene Therapies
- Administration
- Intraretinal
01
Overview
MCO-020 is a preclinical, non-viral gene therapy developed by Nanoscope Therapeutics for the treatment of geographic atrophy secondary to advanced age-related macular degeneration (AMD). The therapy utilizes targeted laser delivery of optogenes—genes encoding light-sensitive proteins—to specific areas of retinal degeneration. This approach aims to restore vision by enabling surviving retinal cells to respond to light, even after photoreceptor loss. Unlike viral vector-based gene therapies, MCO-020 employs a non-viral method for delivering its genetic payload, potentially offering advantages in safety and repeat dosing. The mechanism of action is based on optogenetic modulation via RHO (rhodopsin) pathways[1][2][4][5].
02
Targets
MCO (Multi-characteristic opsin)
Beyond the preview
Go deeper on MCO-020.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MCO-020.